title: [The use of cytoflavin in reperfusion in ischemic stroke].
abstract: OBJECTIVE
  to study the efficacy of cytoflavin in thrombolytic treatment of patients with acute ischemic stroke (IS).
  
  
  METHODS
  Fifty-five patients in the acute stage of IS were examined. The National Institutes of Health Stroke scale (NIHSS), the Rankin scale and the Barthel index of activities of daily living were used. Depending on the scheme of treatment, patients were divided into 2 groups: the first (basic) group included 29 patients who received cytoflavin immediately after thrombolytic therapy. The control group (26 patients) received basic vascular and neuroprotective treatment.
  
  
  CONCLUSIONS
  The marked reduction in the severity of neurological symptoms to the 10th day of treatment and higher probability of a successful outcome were noted in the basic group compared to the controls. There was an improvement of functional activities according to the Rankin scale and of activities of daily living assessed by the Barthel index, with scores "moderate dependence" in the basic group and "severe dependence" in the control group. The inclusion of cytoflavin in the treatment scheme of patients with acute IS increased the efficacy of treatment.
authors.affiliation: Burdenko Voronezh State Medical University, Voronezh City Clinical Emergency Hospital #1, Voronezh; Burdenko Voronezh State Medical University, Voronezh City Clinical Emergency Hospital #1, Voronezh.
authors.forename: I E
authors.initials: IE
authors.lastname: Sazonov
authors.affiliation: Burdenko Voronezh State Medical University, Voronezh City Clinical Emergency Hospital #1, Voronezh.
authors.forename: I V
authors.initials: IV
authors.lastname: Lavrenteva
authors.affiliation: Burdenko Voronezh State Medical University, Voronezh City Clinical Emergency Hospital #1, Voronezh.
authors.forename: N P
authors.initials: NP
authors.lastname: Golovina
mesh_terms: D000203:Activities of Daily Living; D002545:Brain Ischemia / Q000178:diet therapy*; D004338:Drug Combinations; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005486:Flavin Mononucleotide / Q000627:therapeutic use*; D006801:Humans; D007290:Inosine Diphosphate / Q000627:therapeutic use*; D009536:Niacinamide / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy*; D013386:Succinates / Q000627:therapeutic use*; D015912:Thrombolytic Therapy; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D005343:Fibrinolytic Agents; D013386:Succinates; C507879:cytoflavin; D009536:Niacinamide; D005486:Flavin Mononucleotide; D007290:Inosine Diphosphate